Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Stephen Lim"'
Autor:
Daniel J. Landsburg, Matthew Frigault, Michael Heim, Stephen Ronan Foley, Brian T. Hill, Christine M. Ho, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Marta Majdan, Aisha Masood, Marcelo C Pasquini, Cameron J. Turtle
Publikováno v:
Blood. 140:1584-1587
Autor:
Ranjan Tiwari, Brian T. Hill, Marcelo C. Pasquini, Daniel J. Landsburg, Aisha Masood, Marta Majdan, Zhen-Huan Hu, Peter A. Riedell, Cameron J. Turtle, Stephen Lim, Christine M. Ho, Stephen Ronan Foley, Caron A. Jacobson, Samantha Jaglowski, Matthew J. Frigault, Frederick L. Locke, Miguel-Angel Perales
Publikováno v:
Blood. 138:429-429
Background: Tisagenlecleucel is an autologous CD19-directed T-cell immunotherapy that provides high rates of durable response, with a manageable safety profile, in adult patients with R/R diffuse large B-cell lymphoma (DLBCL). An overall response (OR
Autor:
James R. Berenson, Daisy Martinez, Tahmineh Safaie, Noemi Silagan, Jennifer To, Tanya M. Spektor, Eli Forouzan, Regina Swift, Benjamin Eades, Shahrooz Eshaghian, Gary Schwartz, Ralph V. Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Robert Vescio
Publikováno v:
Blood. 138:2727-2727
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with intermediate or high-risk myelofibrosis and polycythemia vera who have had an inadequate response to or are intol
Autor:
Honghao Hank Yang, Robert Vescio, Stephen Lim, James R. Berenson, Tanya M. Spektor, Benjamin Eades, Gary T. Schwartz, Armando Sanchez, Daisy Martinez, Eli Forouzan, Jennifer To, Noemi Silagan, Shahrooz Eshaghian, Ralph V. Boccia, Regina A. Swift
Publikováno v:
Blood. 136:36-36
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with intermediate or high-risk myelofibrosis and polycythemia vera who have had an inadequate response to or are intol
Autor:
James R. Berenson, Jennifer To, Tanya M. Spektor, Daisy Martinez, Armando J. Sanchez, Carley Turner, Regina Swift, Benjamin Eades, Gary Schwartz, Shahrooz Eshaghian, Laura V. Stampleman, Robert A. Moss, Youram Nassir, Ravindranath Patel, Alberto Bessudo, Daniel Greenwald, Ralph V. Boccia, Stephen Lim, Robert Vescio
Publikováno v:
Blood. 134:1903-1903
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea or intermediate or high
Patient Profile and Treatment Patterns in a Commercially Insured Population with Follicular Lymphoma
Publikováno v:
Blood. 134:5880-5880
Introduction: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere. Patient characteristics and burden of FL are incomplete and vary from previous studies. This study evaluated patient profile, including
Autor:
To Jennifer, Ravindranath Patel, Shahrooz Eshaghian, Carley Turner, Gary T. Schwartz, Stephen Lim, Alberto Bessudo, Robert A. Moss, Benjamin Eades, Laura Stampleman, Robert Vescio, Tanya M. Spektor, Regina A. Swift, James R. Berenson
Publikováno v:
Blood. 132:1988-1988
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea or intermediate or high
Autor:
Ian W. Flinn, Cesar O. Freytes, Edmund K. Waller, Terrance Comeau, Luciano J. Costa, Thomas C. Shea, Agnes Elekes, Kazunobu Kato, Michael A. Pulsipher, Philip J. Bierman, Stephen Lim, Michael Lill, Louie H. Yu, Isabelle Bence-Bruckler, Shiva Patil, Yiping Sun, Tsiporah B. Shore, Michael Craig, Rosa F. Yeh, Tulio E. Rodriguez, Pierre Laneuville, Angela Smith, Robert K. Stuart, Elizabeth Armstrong, William P. Vaughan, Andy I. Chen
Publikováno v:
Blood. 120:813-813
Abstract 813 Background: Published reports indicate that oral or intravenous (IV) busulfan in combination with cyclophosphamide and VP-16 (BuCyVP-16) is an effective conditioning regimen with acceptable safety profile for lymphoma patients prior to a
Autor:
Michael Lill, Amir Steinberg, Angela M. Lopez, Stephen Lim, Steven Kwon, Mercedes M. Franco, Catherine Bresee
Publikováno v:
Blood. 116:4589-4589
Abstract 4589 Background: Burkitt lymphoma is a highly aggressive and rapidly proliferating hematologic malignancy. Various chemotherapy regimens (HyperCVAD, CODOX-M/IVAC, REPOCH) have been shown to improve overall survival rate. However, in instance
Publikováno v:
Blood. 106:3730-3730
Background: Paroxysmal cold hemaglobinuria (PCH) is caused by an IgG autoantibody which behaves as a biphasic hemolysin, attaching to RBCs at cold temperatures and activating complement at warmer temperatures, leading to hemolysis. This antibody, kno